Opioid Dependence Treatment Market Players:
- Orexo AB
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT AnalysisÂ
- Indivior PLC
- Titan Pharmaceuticals, Inc.
- Viatris Inc.
- Pfizer, Inc.
- Hikma Pharmaceuticals PLC
- BioDelivery Sciences International Inc.
- Teva Pharmaceutical Industries Ltd.
- Alkermes
- Camurus AB
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of opioid dependence treatment is estimated at USD 4.23 billion.
The global opioid dependence treatment market size crossed USD 3.89 billion in 2025 and is likely to register a CAGR of over 9.7%, exceeding USD 9.82 billion revenue by 2035.
Asia Pacific is projected to command a 39.1% revenue share by 2035 in the opioid dependence treatment market, propelled by rising awareness of opioid use disorder and a substantial patient pool across the region.
Key players in the market include AstraZeneca PLC, FibroGen, Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Sunovion Pharmaceuticals Inc., Aurobindo Pharma Limited, Zydus Pharmaceuticals Inc.
